ARTICLE | Clinical News
NHPN-1010: Phase I started
January 5, 2015 8:00 AM UTC
In November, Otologic said it began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single doses of 500, 1,000 and 1,500 mg oral HPN-07 alone and HPN-07 at the maximum tolerated dos...